1. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary
- Author
-
Laura A. Magee, Anouk Pels, Michael Helewa, Evelyne Rey, Peter von Dadelszen, Francois Audibert, Emmanuel Bujold, Anne-Marie Côté, Myrtle Joanne Douglas, Genevieve Eastabrook, Tabassum Firoz, Paul Gibson, Andrée Gruslin, Jennifer Hutcheon, Gideon Koren, Ian Lange, Line Leduc, Alexander G. Logan, Karen L. MacDonell, Jean-Marie Moutquin, and Ilana Sebbag
- Subjects
Gestational hypertension ,medicine.medical_specialty ,Pediatrics ,MEDLINE ,Long-term prognosis ,Maternal outcome ,Preeclampsia ,Pregnancy ,Diagnosis evaluation ,medicine ,Humans ,Executive summary ,business.industry ,Obstetrics ,Obstetrics and Gynecology ,Perinatal outcome ,Guideline ,Hypertension, Pregnancy-Induced ,medicine.disease ,Blood pressure ,Hypertension ,Female ,business - Abstract
Objective: This executive summary presents in brief the current evidence assessed in the clinical practice guideline prepared by the Canadian Hypertensive Disorders of Pregnancy Working Group and published by Pregnancy Hypertension (. http://www.pregnancyhypertension.org/article/S2210-7789(14)00004-X/fulltext) to provide a reasonable approach to the diagnosis, evaluation, and treatment of the hypertensive disorders of pregnancy. Evidence: Published literature was retrieved through searches of Medline, CINAHL, and The Cochrane Library in March 2012 using appropriate controlled vocabulary (e.g., pregnancy, hypertension, pre-eclampsia, pregnancy toxemias) and key words (e.g., diagnosis, evaluation, classification, prediction, prevention, prognosis, treatment, postpartum follow-up). Results were restricted to systematic reviews, randomized control trials, controlled clinical trials, and observational studies published in French or English between January 2006 and February 2012. Searches were updated on a regular basis and incorporated in the guideline to September 2013. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies. Values: The quality of evidence in the guideline summarized here was rated using the criteria described in the Report of the Canadian Task Force on Preventative Health Care (. Table 1).
- Published
- 2014